Amgen ’s Mimpara for secondary HPT children with ESRD receives marketing approval in EU

US-based biopharmaceutical company Amgen has been granted marketing authorisation by the European Commission (EC) for Mimpara (cinacalcet) to treat secondary hyperparathyroidism (HPT) in children with end ‑stage renal disease (ESRD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news